Iroquois Capital Management LLC 13D and 13G filings for Biodexa Pharmaceuticals Plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:12 pm Sale | 2024-09-30 | 13G | Biodexa Pharmaceuticals Plc BDRX | Iroquois Capital Management LLC | 112,077 0.670% | -44,718,963 (-99.75%) | Filing |
| 2024-08-08 4:24 pm Purchase | 2024-07-19 | 13G | Biodexa Pharmaceuticals Plc BDRX | Iroquois Capital Management LLC | 44,831,040 9.990% | 44,831,040 (New Position) | Filing |
| 2024-08-05 09:00 am Purchase | 2024-07-19 | 13G | Biodexa Pharmaceuticals Plc BDRX | Iroquois Capital Management LLC | 44,831,040 9.990% | 44,831,040 (New Position) | Filing |